ImmunoQure AG - People
Dr. Edward Stuart

Dr. Edward Stuart

Dr. Edward Stuart, Chairman of the Board

Ed started his industrial career as COO of DeveloGen AG before co-founding and becoming the Managing Director and CBO of U3 Pharma AG. Subsequently, Ed became the founding CEO of Neurimmune Therapeutics AG. He also acted as the founding CEO of CT Atlantic AG (Zurich, Switzerland), an oncology-focused spin-off from the University of Zurich and the Ludwig Institute for Cancer Research and is a co-founder of HS LifeSciences and QureInvest. He studied pharmacology in University College Dublin, Ireland, where he was awarded his Ph.D. and was a post-doctoral scientist at the Max Planck Institute in Gottingen followed by his appointment as a Lecturer in Medical Genetics in Imperial College London, UK. Ed also holds an MBA from The Business School of Imperial College London, UK.

Prof. Adrian Hayday

Prof. Adrian Hayday

Prof. Adrian Hayday, Member of the Board

Adrian Hayday is Kay Glendinning Professor of Immunobiology at King’s College London; co-lead of the Clinical Academic Grouping in Genetics Rheumatology, Immunology, Infection, and Dermatology at Kings’ affiliated hospitals; and a Senior Group Leader at the London Research Institute, Cancer Research UK. He graduated in biochemistry from Cambridge; earned a PhD in virology from London University; and undertook post-doctoral training at M.I.T., before his appointment (at age 28) to the Yale University faculty, where he rose to Full-Professor and was awarded the DeVane Medal, Yale’s highest honor for scholarship and teaching. He returned to restructure immunology at King’s in 1998. He co-discovered the unanticipated “gamma-delta” T cell antigen receptor, provoking widespread interest in immune cell function within tissues, and tumor immune surveillance. His active research team has published almost 200 papers, with 33 published in cross-disciplinary journals, Nature, Science, Cell, or Proceedings of the National Academy. He won the King’s College Award for Business in 2009; has served on numerous scientific advisory and investor advisory boards, and has chaired funding panels for the Welcome Trust and the American Cancer Society.

Christina Hertel

Christina Hertel

Dr. Christina Hertel, Project and Data Manager

Christina is in charge of project management of ImmunoQure’s portfolio of assets and coordinating activities within the company, its partners and founding laboratories. Christina started out as a scientific associate for HS LifeSciences and has been working with ImmunoQure since it’s foundation. She studied molecular biology at the University of Aarhus, DK, and earned her PhD from the University of Munich, DE.

Dr. Pärt Peterson

Dr. Pärt Peterson

Dr. Pärt Peterson, University of Tartu, Estonia

Pärt Peterson is Professor of Molecular Immunology at the University of Tartu, Estonia. He graduated in molecular biology from the University of Tartu and defended his PhD on molecular immunology in 1996 at the University of Tampere, Finland. He spent his postdoctoral period in the Institute of Medical Technology where his research interest focused on the Autoimmune Regulator (AIRE) gene, the key factor in central thymic tolerance. He also co-discovered DANN methyltransferase 3-like (DNMT3L) gene, a regulator of DNA methylation and epigenetic imprinting. He obtained the degree of Docent at the University of Tampere and in 2000 became a Fellow of the Finnish Academy. In 2003-2009 he was supported by The Wellcome Trust as International Senior Fellow and started a research group as Professor of Molecular Pathology at the University of Tartu, and later on in 2008, as Professor of Molecular Immunology. In 2009 he was elected as the Research Professor of the Academy of Estonia. Pärt is the recipient of the Estonian Science Prize (2008), and has more than 100 research publications on various aspects of immunology and molecular biology.

Dr. Kai Kisand

Dr. Kai Kisand

Dr. Kai Kisand, University of Tartu, Estonia

Kai Kisand got her MD from the University of Tartu, Estonia and earned a PhD from the same university in 1999. She undertook post-doctoral training at the Uppsala University, Sweden. Currently she is the Senior Research Fellow at the Institute of Biomedicine, University of Tartu and the board member of the Estonian Society for Immunology and Allergology. Her major research interests are related to autoimmunity and self-tolerance, among the other projects dissecting the role of autoimmune regulator (AIRE) and its deficiency in the disease pathogenesis (APECED, Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy). She is also involved in teaching immunology to medical students, has been organizing many international immunology courses and meetings and is supervising several PhD studies.

Prof. Annamari Ranki

Prof. Annamari Ranki

Prof. Annamari Ranki, University of Finland, HUCH, Helsinki

Annamari Ranki is Professor of Dermatology and Venereology at the University of Helsinki, Helsinki Finland, and the Chairperson of the Department of Skin and Allergic Diseases at the Skin and Allergy Hospital, Helsinki University Central Hospital (HUCH), Helsinki, Finland, since 1997.

Prof. Ranki became M.D. in 1977 and defended her Ph.D. thesis on lymphocyte subsets in 1978. She specialized in dermatology in Helsinki University Central Hospital and oriented her research in studies on immune responses in rheumatoid arthritis, lupus erythematosus and various skin diseases. She became specialist in 1983 and received her docent ship the same year. Since 1994, she has been appointed as Professor of Dermatology and department head at the University of Oulu and at the University of Tampere.
In 1983 Annamari Ranki started studying on a new disease, AIDS. This research resulted in several original publications and collaboration with Dr. Robert Gallo. She joined Gallo’s lab for two years at the National Cancer Institute, NIH, in Bethesda, and also worked in Memorial Sloan-Kettering Cancer Center in New York in 1985-87. After returning to Finland she continued studies on HIV immunology and vaccine development together with Prof. Kai Krohn. This work resulted in a novel DNA-based HIV vaccine candidate, currently being tested in clinical trials. During the past 15 years her group has studied mostly molecular pathogenesis of cutaneous T-cell lymphomas but also the autoinflammatory periodic fever syndrome TRAPS. Prof. Ranki has published ca. 230 scientific papers.
Prof. Ranki has been active in research politics both at national and international level. She is a member of the Finnish Academy of Science and Letters and Knight, First Class of the Order of the White Rose of Finland. She has also been awarded the International League of Dermatological Societies (ILDS) Certificate of Appreciation in 2010.

Prof. Kai Krohn

Prof. Kai Krohn

Prof. Kai Krohn, University of Finland, HUCH, Helsinki

Professor Kai Krohn completed his medical training (MD) at the Medical School of the University of Helsinki, Finland in 1962 and obtained his PhD in 1968. During 1962 – 1968 he served as intern at University Children´s Hospital, and at the Department of Pathology. In 1970 he obtained his degree of Specialist in Pathology (Boards).

During 1962 – 1969 his research concentrated in auto-immunity, and he published several papers on clinical immunological disease, notably of chronic autoimmune gastritis and on the autoimmune syndrome (APECED).

Prof.. Krohn spent his post-doctoral fellowship at New York Medical Hospital, Cornell University and at the Virus laboratory in New York Blood center, with Dr. Alfred M. Prince. They characterized the newly found virus for serum hepatitis, the Hepatitis B-virus and with the company Electronucleonics, took the first steps in the development of the HBV vaccine.

After his post-doctoral period, Dr. Krohn was elected to become Assistant Professor of Pathology at Helsinki University and in 1974 he was elected to be the first Professor of Pathology at the newly established Medical School at Tampere University. During his years at Tampere University, he served as the Chairman of the University Council and as the Vice-Dean twice. In 1995 he was elected to become the first Director of the newly established Institute of Medical Biotechnology (IMT).

In addition to the Hepatiti